Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA and CV01 Ultrasound for Sonodynamic Therapy in High-Grade Glioma
NCT06665724Phase 1Completed
- Sponsor
- Universität Münster
- Start
- Jan 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 5-aminolevulinic acid in glioma, sponsored by Universität Münster. Primary endpoint: Safety and tolerability at 28 days. Started Jan 2025; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06665724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06665724.